<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03747497</url>
  </required_header>
  <id_info>
    <org_study_id>MRX4-201</org_study_id>
    <nct_id>NCT03747497</nct_id>
  </id_info>
  <brief_title>Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicuRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicuRx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether contezolid acefosamil is as safe and
      effective as linezolid in the treatment of adult patients with acute bacterial skin and skin
      structure infections
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Actual">March 26, 2019</completion_date>
  <primary_completion_date type="Actual">March 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early clinical response in the ITT population</measure>
    <time_frame>48-72 hours</time_frame>
    <description>Number of patients at the early assessment visit with a 20% reduction in ABSSSI lesion size compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>Screening through Day 42</time_frame>
    <description>Number of patients with adverse events as a measure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early clinical response in the mITT and micro-ITT population</measure>
    <time_frame>48-72 hours</time_frame>
    <description>Number of MITT and micro-ITT patients at the early assessment visit with a 20% reduction in ABSSSI lesion size compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigators assessment of clinical response</measure>
    <time_frame>End of therapy which is after 10 to 14 days of study drug; post therapy evaluation, 7 to 14 days after the end of therapy; long term follow-up, 21 to 28 days after the end of therapy</time_frame>
    <description>Change in baseline ABSSSI signs and symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response</measure>
    <time_frame>post therapy evaluation, 7 to 14 days after the end of therapy</time_frame>
    <description>Measurement of the presence or absence of the original pathogen in patient infection site samples or blood cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in lesion size</measure>
    <time_frame>Day 7</time_frame>
    <description>Percent change in lesion size</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Skin Diseases, Bacterial</condition>
  <condition>Gram-Positive Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>contezolid acefosamil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>contezolid acefosamil 1500 mg IV x 1 dose, followed by 1000 mg IV q12h for at least 3 total IV doses, followed by 1300 mg PO q12h for 10 to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>linezolid 600 mg IV q12h for at least 3 total IV doses, followed by 600 mg PO q12h for 10 to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>contezolid acefosamil</intervention_name>
    <description>IV and oral contezolid acefosamil given twice a day for 10 to 14 days</description>
    <arm_group_label>contezolid acefosamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid 600 mg</intervention_name>
    <description>IV and oral linezolid given twice a day for 10 to 14 days</description>
    <arm_group_label>linezolid</arm_group_label>
    <other_name>zyvox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with systemic signs of infection diagnosed with acute bacterial skin and skin
             structure infection (ABSSSI)

          -  Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections

        Exclusion Criteria:

          -  Uncomplicated skin infections

          -  Severe sepsis or septic shock

          -  ABSSSI solely due to gram-negative pathogens

          -  Prior systemic antibiotics within 96 hours of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>eStudy Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Clinical Trials</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Medical Associates</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical Group</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jubilee Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudy Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABSSI</keyword>
  <keyword>Acute bacterial skin and skin structure infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

